Hypofractionation May Be Poised to Become New Standard of Care for Prostate Cancer


“There has been an ongoing debate about which type of radiation therapy is preferable in the treatment of localized prostate cancer: hypofractionation (larger fractions given over 4–5 weeks) or conventional radiotherapy (given over 8–9 weeks). A new study presented at the 2016 ASCO Annual Meeting may help to resolve that debate.

“The large, randomized trial found that hypofractionation was not inferior to conventional radiation therapy in terms of efficacy or safety in men with localized intermediate-risk prostate cancer. This is the third large, randomized, contemporary study to demonstrate that both techniques have equivalent efficacy and safety.”

Go to full article.

Do you have questions about this story? Let us know in a comment below. If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our Ask Cancer Commons service.